STOCK MARKET BLOG APRIL 2024

by the CEO Silvano Grimaldi of the independent asset management company GRIMALDI & PARTNERS AG

MONTHLY REVIEW

International stock markets ended the month of APRIL with losses.

DRIVING FACTORS

In the wake of a robust economic situation in the US, hopes for rapid easing by the US Federal Reserve have diminished.
Persistent concerns about stubbornly high inflation.
Continued rise in bond yields .
US labor costs rose more than expected at the beginning of the year.
US house prices have risen more than expected.

EQUITIES IN FOCUS

NOVARTIS surprises with figures and new president

After a strong start to 2024, the pharmaceutical company is raising its targets for the full year. And it has already found a successor for the chairmanship of the board of directors for the coming year.

The growth was driven by drugs such as the heart drug Entresto, the psoriasis drug Cosentyx, Kesimpta (MS), Kisqali (breast cancer) as well as the radioligand therapy Pluvicto and the cholesterol-lowering drug Leqvio.

Novartis earned 3.4 billion US dollars (+29%) in the first quarter. The bottom line was a group profit of 2.7 billion, compared to just under 2.2 billion in the same period last year. The increase is mainly due to the overall improvement in ........

.............................................................................

.......................................................................

.............................................

..........................................

........................................

Please order the full version of our stock market blog or subscribe.

Simply send us your request by email to info@grimaldi-partners.ch

Thank you for your interest!